Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

FTO-Mediated mRNA Demethylation Drives Leukemogenesis

DOI: 10.1158/2159-8290.CD-RW2017-006 Published February 2017
  • Article
  • Info & Metrics
Loading
  • Major finding: The mRNA demethylase FTO promotes leukemogenesis and inhibits ATRA-mediated differentiation.

  • Mechanism: FTO demethylates m6A sites in the 3′-UTRs of ASB2 and RARA to decrease ASB2 and RARA mRNA stability.

  • Impact: Targeting FTO may be a potential therapy, alone or in combination with ATRA, for patients with AML.

N6-methyladenosine (m6A) methylation is the most common type of mRNA modification and may impact biological regulation analogous to the well-studied reversible DNA and histone modifications. FTO, the first RNA demethylase to be identified, is associated with increased body mass and obesity, but its role in oncogenesis has not been investigated. To determine the impact of FTO in tumorigenesis, Li and colleagues interrogated the role of FTO in acute myeloid leukemia (AML). FTO was shown to be highly overexpressed in AMLs with t(11q23)/MLL rearrangements, t(15;17)/PML-RARA, FLT3-ITD, and/or NPM1 mutations, all of which directly upregulated expression of FTO. Overexpression of FTO resulted in decreased global m6A levels and increased cell growth, resistance to apoptosis, and transformation; similarly, knockdown of FTO in these leukemia cell lines resulted in the opposite phenotype. Further, FTO overexpression accelerated leukemogenesis, whereas FTO knockdown delayed the onset of AML, in mouse bone marrow transplantation assays. Simultaneous m6A and RNA sequencing of FTO-overexpressing and control AML cell lines identified genes potentially regulated by FTO; among these, ankyrin repeat and SOCS box containing 2 (ASB2) and retinoic acid receptor alpha (RARA) were significantly hypomethylated and downregulated in FTO-overexpressing cells. Similarly, expression of ASB2 and RARA was inversely correlated to FTO expression in human AML cohorts, and expression or ablation of FTO expression resulted in, respectively, ablation or expression of ASB2 and RARA; knockdown of ASB2 or RARA promoted AML cell growth and viability and rescued the antileukemogenic effects of FTO knockdown. Further, FTO was shown to negatively regulate the stability of ASB2 and RARA transcripts via m6A sites in the ASB2 and RARA 3′-UTRs, and expression of FTO inhibited all-trans retinoic acid (ATRA)–mediated differentiation of AML cells. Together, these findings elucidate the role of FTO in leukemogenesis and suggest that inhibition of FTO, particularly in combination with ATRA, may be a potential therapy for patients with FTO-overexpressing AMLs.

Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell 2017;31:127–41.

  • ©2017 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 7 (2)
February 2017
Volume 7, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
FTO-Mediated mRNA Demethylation Drives Leukemogenesis
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
FTO-Mediated mRNA Demethylation Drives Leukemogenesis
Cancer Discov February 1 2017 (7) (2) OF9; DOI: 10.1158/2159-8290.CD-RW2017-006

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
FTO-Mediated mRNA Demethylation Drives Leukemogenesis
Cancer Discov February 1 2017 (7) (2) OF9; DOI: 10.1158/2159-8290.CD-RW2017-006
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • In Vivo CRISPR Screen Identifies FLI1 as Regulator of Effector T Cells
  • Trial Supports Combination Treatment and New Target for Multiple Myeloma
  • Mitochondrial DNA Damage Triggers an IFN-Mediated Immune Response
Show more Research Watch

Leukemia

  • IFITM3 Enhances PI3K Pathway Signaling to Promote B-cell Malignancies
  • The Oncogenes STAT5 and ERK Have Opposing Roles in Leukemogenesis
  • Preleukemic Cells Can Be Eliminated in NPM1-Mutant Acute Myeloid Leukemia Models
Show more Leukemia
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement